Question 1

Who are the top researchers at Biocartis (Belgium)?

Accepted Answer

Ranked on the quality score, Benoit Devogelaere, Tania Ivens and Evelien Rondelez lead among researchers whose main affiliation is Biocartis (Belgium).

Question 2

What are the most cited papers from Biocartis (Belgium)?

Accepted Answer

The most cited paper from Biocartis (Belgium) is "Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors" (Max S. Schreuer, Geert Meersseman, Sari Van Den Herrewegen et al., 2016), with 141 citations. Next come "Comparison of Pathogen DNA Isolation Methods from Large Volumes of Whole Blood to Improve Molecular Diagnosis of Bloodstream Infections" (88) and "BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System" (78).

Question 3

Which research topics does Biocartis (Belgium) publish most on?

Accepted Answer

By volume in 2022-now: Advanced Biosensing Techniques and Applications, Cell Image Analysis Techniques, Advanced Breast Cancer Therapies and Cancer Genomics and Diagnostics.

Question 4

Which keywords describe research at Biocartis (Belgium)?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Targeted Therapy, Cancer Genomics, Mutational Signatures, Molecular Characterization, Hereditary Syndromes, Microsatellite Instability, Immune Response and Precision Medicine.

Question 5

Which fields of science does Biocartis (Belgium) work in?

Accepted Answer

In all years, 53% of research at Biocartis (Belgium) is in Health Sciences, 40% in Life Sciences. Its largest fields are Medicine (53%), Biochemistry, Genetics and Molecular Biology (33%), Immunology and Microbiology (6%). It does 1.9× the world's share of Life Sciences.

Question 6

Is Biocartis (Belgium)'s research output growing?

Accepted Answer

Output in 2022-2025 was 11% lower than in 2018-2021.